[
    [
        {
            "time": "2018-07-26",
            "original_text": "Allergan Reports Strong Revenue Growth and Q2 2018 Earnings",
            "features": {
                "keywords": [
                    "Allergan",
                    "Strong Revenue Growth",
                    "Q2 2018 Earnings"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Allergan Reports Strong Revenue Growth and Q2 2018 Earnings",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-07-27",
            "original_text": "Celgene Raises Revenue Guidance after Solid Growth in Q2 2018",
            "features": {
                "keywords": [
                    "Celgene",
                    "Revenue Guidance",
                    "Solid Growth",
                    "Q2 2018"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Celgene Raises Revenue Guidance after Solid Growth in Q2 2018",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-07-25",
            "original_text": "Analysts’ Recommendations for Sanofi Stock before Q2 Results",
            "features": {
                "keywords": [
                    "Analysts’ Recommendations",
                    "Sanofi",
                    "Q2 Results"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Analysts’ Recommendations for Sanofi Stock before Q2 Results",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-07-26",
            "original_text": "AstraZeneca's (AZN) Q2 Earnings and Sales Beat, Stock Up",
            "features": {
                "keywords": [
                    "AstraZeneca",
                    "Q2 Earnings",
                    "Sales Beat",
                    "Stock Up"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AstraZeneca's (AZN) Q2 Earnings and Sales Beat, Stock Up",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-07-26",
            "original_text": "Allergan (AGN) Beats on Q2 Earnings, Unveils Buyback Plan",
            "features": {
                "keywords": [
                    "Allergan",
                    "Q2 Earnings",
                    "Buyback Plan"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Allergan (AGN) Beats on Q2 Earnings, Unveils Buyback Plan",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-07-26",
            "original_text": "Glaxo (GSK) Q2 Earnings & Sales Beat Estimates, '18 View Up",
            "features": {
                "keywords": [
                    "Glaxo",
                    "Q2 Earnings",
                    "Sales Beat",
                    "Estimates",
                    "'18 View Up"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Glaxo (GSK) Q2 Earnings & Sales Beat Estimates, '18 View Up",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-07-24",
            "original_text": "LLY Crosses Above Average Analyst Target",
            "features": {
                "keywords": [
                    "LLY",
                    "Crosses Above",
                    "Average Analyst Target"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "LLY Crosses Above Average Analyst Target",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-07-26",
            "original_text": "Glaxo (GSK) Q2 Earnings & Sales Beat Estimates, '18 View Up",
            "features": {
                "keywords": [
                    "Glaxo",
                    "Q2 Earnings",
                    "Sales Beat",
                    "Estimates",
                    "'18 View Up"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Glaxo (GSK) Q2 Earnings & Sales Beat Estimates, '18 View Up",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-07-27",
            "original_text": "ABBV, MRK Q2 Earnings on Jul 27: Here are the Key Predictions",
            "features": {
                "keywords": [
                    "ABBV",
                    "MRK",
                    "Q2 Earnings",
                    "Key Predictions"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "ABBV, MRK Q2 Earnings on Jul 27: Here are the Key Predictions",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-07-23",
            "original_text": "Initiating Free Research Reports on Pfizer and Three Other Drug Makers Equities",
            "features": {
                "keywords": [
                    "Free Research Reports",
                    "Pfizer",
                    "Drug Makers Equities"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Initiating Free Research Reports on Pfizer and Three Other Drug Makers Equities",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-07-25",
            "original_text": "FOCUS-Amgen's new migraine drug hits insurance hurdles",
            "features": {
                "keywords": [
                    "Amgen",
                    "migraine drug",
                    "insurance hurdles"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "FOCUS-Amgen's new migraine drug hits insurance hurdles",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]